Endocyte, Inc. (NASDAQ:ECYT) - Research analysts at Wedbush lowered their Q3 2017 EPS estimates for Endocyte in a report released on Thursday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter, down from their previous estimate of ($0.22). Wedbush has a “Neutral” rating and a $2.00 price objective on the stock. Wedbush also issued estimates for Endocyte’s Q4 2017 earnings at ($0.19) EPS, FY2017 earnings at ($0.97) EPS, Q1 2018 earnings at ($0.20) EPS, Q2 2018 earnings at ($0.20) EPS, Q3 2018 earnings at ($0.21) EPS, Q4 2018 earnings at ($0.21) EPS and FY2018 earnings at ($0.82) EPS.
ECYT has been the topic of several other research reports. ValuEngine cut Endocyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Cowen and Company cut Endocyte from an “outperform” rating to a “market perform” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research upgraded Endocyte from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research note on Thursday, June 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. Endocyte presently has an average rating of “Hold” and a consensus target price of $3.58.
TRADEMARK VIOLATION NOTICE: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/15/wedbush-weighs-in-on-endocyte-inc-s-q3-2017-earnings-nasdaqecyt.html.
Endocyte (NASDAQ ECYT) opened at 1.35 on Monday. Endocyte has a 1-year low of $1.32 and a 1-year high of $3.49. The company’s 50-day moving average price is $1.44 and its 200-day moving average price is $2.03. The stock’s market cap is $57.33 million.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.03. The firm had revenue of $0.01 million for the quarter. Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. During the same quarter in the previous year, the company earned ($0.25) EPS.
A number of hedge funds have recently made changes to their positions in the stock. Algert Global LLC purchased a new stake in shares of Endocyte during the first quarter valued at about $345,000. Teachers Advisors LLC boosted its stake in shares of Endocyte by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 9,506 shares during the last quarter. Stoneridge Investment Partners LLC boosted its stake in shares of Endocyte by 40.0% in the first quarter. Stoneridge Investment Partners LLC now owns 57,406 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16,399 shares during the last quarter. RMB Capital Management LLC boosted its stake in shares of Endocyte by 8.8% in the first quarter. RMB Capital Management LLC now owns 264,885 shares of the biopharmaceutical company’s stock valued at $681,000 after buying an additional 21,500 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Endocyte by 2.7% in the fourth quarter. State Street Corp now owns 620,248 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 16,289 shares during the last quarter. Hedge funds and other institutional investors own 32.67% of the company’s stock.
About Endocyte
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
